4/23
08:09 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Medium
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
4/11
08:06 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
4/10
07:05 am
mltx
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions [Yahoo! Finance]
Low
Report
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions [Yahoo! Finance]
4/10
07:00 am
mltx
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
Low
Report
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
4/10
07:00 am
mltx
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions
Low
Report
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions
4/9
08:09 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.
4/2
08:10 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $62.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $62.00 price target on the stock.
3/18
03:15 pm
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $92.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $92.00 price target on the stock.
3/15
11:53 am
mltx
MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business [Yahoo! Finance]
Medium
Report
MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business [Yahoo! Finance]
3/10
12:07 pm
mltx
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day [Yahoo! Finance]
Medium
Report
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day [Yahoo! Finance]
3/10
12:00 pm
mltx
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
Medium
Report
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
3/4
08:09 am
mltx
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 [Yahoo! Finance]
Medium
Report
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 [Yahoo! Finance]
3/4
08:06 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Medium
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
3/4
08:00 am
mltx
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
Medium
Report
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
3/1
09:03 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $92.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $92.00 price target on the stock.
3/1
08:15 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.
3/1
12:53 am
mltx
Insider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX) [Yahoo! Finance]
Medium
Report
Insider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX) [Yahoo! Finance]
2/29
08:14 am
mltx
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 [Yahoo! Finance]
High
Report
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 [Yahoo! Finance]
2/29
08:00 am
mltx
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
High
Report
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
2/26
05:39 pm
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at William Blair. They now have a $92.00 price target on the stock.
Medium
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at William Blair. They now have a $92.00 price target on the stock.
2/26
08:18 am
mltx
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS) [Yahoo! Finance]
Low
Report
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS) [Yahoo! Finance]
2/26
08:00 am
mltx
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
Low
Report
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
2/25
08:27 pm
mltx
MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3 [Seeking Alpha]
Low
Report
MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3 [Seeking Alpha]
2/20
11:55 pm
mltx
Insider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake Immunotherapeutics [Yahoo! Finance]
Medium
Report
Insider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake Immunotherapeutics [Yahoo! Finance]
2/15
07:17 am
mltx
MoonLake Immunotherapeutics (NASDAQ: MLTX) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $77.00 price target on the stock.
Medium
Report
MoonLake Immunotherapeutics (NASDAQ: MLTX) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $77.00 price target on the stock.